Are we asking too much of our trials?

American Heart Journal

Volumn 143, Issue 1, 2002, Pages 1-3

  Skali, Hicham ^a   Solomon, Scott D ^a   Pfeffer, Marc A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOLOGY; CAUSE OF DEATH; CLINICAL TRIAL; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SIGNAL NOISE RATIO;

EID: 0036142758     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.119771     Document Type: Article

References (32)

1. Randomised controlled trials in cardiovascular medicine: Past achievements, future challenges
2. The governance of clinical trials
3. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Report of the Committee of Principal Investigators
4. Lipid Research Clinics Coronary Primary Prevention Trial results, I: The relationship of reduction in incidence of caronary heart disease
5. Lipid Research Clinics Coronary Primary Prevention Trial results, II: The relationship of reduction in incidence of caronary heart disease to cholesterol lowering
6. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
7. Might treatment of hyperchobsterolaemia increase noncardiac mortality?
8. Cholesterol and noncardiac mortality
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
11. Prevention of cardiovascular events death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
12. Statins prevent coronary heart disease
13. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
14. Use of composite end-points in thrombolysis trials of acute myocardial infarction
15. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
16. Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5): Thrombosis In Myocardial Infarction
17. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
18. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events
19. Lipid-lowering therapy in acure coronary syndromes
20. The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials
21. An approach to evaluating thrombolytic therapy in acute myocardial infarction: The "unsatisfactory outcome" end point
22. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study
23. Effects of enalapril on mortality in severe cangestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
24. Effect of oral milrinone on mortality in severe chronic heart failure: The PROMISE Study Research Group
25. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
26. The effect of digoxin on mortality and morbidity in patients with heart failure
27. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
28. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
29. Effect of carvedilol on survival in severe chronic heart failure
30. Are surrogate markers adequate to assess cardiovascular disease drugs?
31. Interobserver discordance in the classification of mechanisms of death in studies of heart failure
32. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: Results with and without the end-point committee's final decision on end-points